Atomic Ai Creates First Large Language Model Using Chemical Mapping Data To Optimize Rna Therapeutic Development

By Author: Arina Smith
Total Articles: 185
Comment this article

Atomic AI Advances RNA Drug Discovery with Innovative ATOM-1™ Platform
Atomic AI, a leading biotechnology company, has unveiled a groundbreaking development in RNA drug discovery with its ATOM-1™ platform. The company's proprietary large language model (LLM) utilizes chemical mapping data, as detailed in a preprint paper on bioRxiv. This platform is a foundation model that accurately predicts the structure and function of RNA, significantly enhancing the development of RNA therapeutics.

Key Highlights:

Foundation Model for RNA Structure: ATOM-1 enables the prediction of structural and functional aspects of RNA, optimizing key characteristics of RNA modalities such as stability, toxicity, and translational efficiency.

Source: Atomic AI
Data Collection and Training: Researchers at Atomic AI collected data on millions of RNA sequences, comprising over a billion nucleotide-level measurements. Trained on this extensive dataset, ATOM-1 has gained a comprehensive understanding of RNA.

Source: Atomic AI
Unique RNA Foundation Model: ATOM-1 outperforms previously published methods, accurately ...
... predicting RNA secondary and tertiary structure. In a retrospective analysis, it surpassed 1,600 other methods for predicting in-solution mRNA stability.

Source: Atomic AI
Broader Applicability: The platform's potential extends beyond structure prediction, offering applications in optimizing various properties of RNA-based medicines, including mRNA vaccine stability and siRNA activity.

Source: Atomic AI
Streamlined Drug Discovery: Atomic AI aims to create a streamlined drug discovery process, advancing its pipeline and collaborating with partners to validate RNA targets and tools efficiently.

Source: Atomic AI
Raphael Townshend's Insight: Founder and CEO of Atomic AI, Raphael Townshend, highlights the unique opportunity with ATOM-1 to predict RNA structure and function with high precision, requiring only a small amount of initial data.

Source: Atomic AI
Significance in RNA Therapeutics:
The recent success of mRNA-based COVID-19 vaccines underscores the potential of RNA-based therapies. However, challenges in designing RNA therapeutics arise from a lack of data to predict RNA structure and function. ATOM-1 addresses this gap by offering a platform that can optimize key characteristics critical for effective RNA therapeutics.

Conclusion:
Atomic AI's ATOM-1 platform represents a significant leap in the field of RNA drug discovery. By harnessing the power of artificial intelligence and structural biology, the company aims to revolutionize the design and discovery of RNA-targeted medicines. The platform's accuracy in predicting RNA structure and function opens new possibilities for the efficient development of therapeutics, contributing to advancements in treating various conditions, from infectious diseases to cancer and neurodegenerative diseases.